Processa Pharmaceuticals Inc [PCSA] Stock trading around $0.23 per share: What’s Next?

MDB

Processa Pharmaceuticals Inc [NASDAQ: PCSA] plunged by -$0.03 during the normal trading session on while it closed the day at $0.23.

Processa Pharmaceuticals Inc stock has also loss -30.67% of its value over the past 7 days. However, PCSA stock has declined by -49.74% in the 3 months of the year. Over the past six months meanwhile, it has lost -82.13% and lost -74.53% year-on date.

The market cap for PCSA stock reached $2.67 million, with 11.88 million shares outstanding and 10.44 million shares in the current float. Compared to the average trading volume of 4.23M shares, PCSA reached a trading volume of 26146569 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Processa Pharmaceuticals Inc [PCSA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PCSA shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PCSA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Processa Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 25, 2024.

The Average True Range (ATR) for Processa Pharmaceuticals Inc is set at 0.06 The Price to Book ratio for the last quarter was 0.34, with the Price to Cash per share for the same quarter was set at 0.24.

PCSA stock trade performance evaluation

Processa Pharmaceuticals Inc [PCSA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -30.67. With this latest performance, PCSA shares dropped by -8.87% in over the last four-week period, additionally sinking by -82.13% over the last 6 months – not to mention a drop of -85.93% in the past year of trading.

Processa Pharmaceuticals Inc [PCSA]: An insightful look at the core fundamentals

Processa Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.93 and a Current Ratio set at 2.93.

Earnings per share (EPS) analysis for Processa Pharmaceuticals Inc [PCSA] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PCSA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Processa Pharmaceuticals Inc go to 42.13%.

Processa Pharmaceuticals Inc [PCSA]: Institutional Ownership

The DBT News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.